Based on this molecular mechanism and the use of BRAF/MEK inhibitors in other tumors harboring the BRAF V600E mutation [48–50], BRAF/MEK inhibitors have emerged as an effective treatment strategy for PCP. Here, BRAF is linked to pneumocystosis.